Skip to NavigationSkip to content

Bayer and Novartis to debut new data at ASH 2015

Published on 30/11/15 at 09:28am
ASH 2014 meeting
Delegates will gather to hear the latest clinical data on blood cancers and other conditions (Credit: American Society of Hematology)

Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, at the American Society of Haematology annual meeting in Orlando on December 5-8.

Bayer will present 11 abstracts demonstrating the latest pre-clinical and clinical data from its oncology and haematology development pipeline at the meeting.

Bayer’s oncology pipeline includes three marketed products and several other compounds in various stages of clinical development. The haematology pipeline includes compounds in various stages of development for haemophilia, sickle cell anaemia, thalassemia and other blood and bleeding disorders.

The company says that “these portfolios and pipelines reflect the company's commitment to delivering science for a better life, prioritising specific targets for intervention with the potential to improve the way that cancer and rare blood and bleeding disorders are treated.”

"We are excited to present the latest data from our expanding haematology and oncology pipelines, as they demonstrate our scientific leadership in bleeding disorders and cancer research," says Dr David Weinreich, Bayer's head of global development for specialty medicine.

Their pharma rivals Novartis will highlight data for drugs for blood cancers, including leukaemias, lymphomas and myelomas, as well as supportive care, rare and difficult-to-treat cancers, and personalised cell therapies.

In a example that may bear fruit in 2016, Novartis and the University of Pennsylvania's Perelman School of Medicine have an exclusive global collaboration to research, develop and commercialise chimeric antigen receptor CAR-T cell therapies for the investigational treatment of cancers. The Swiss firm will present new data on investigational CAR-T therapy CTL019, as well as new research for pipeline compound ABL001, a small molecule that could potentially treat chronic myeloid leukaemia.

Novartis will also present clinical data for its existing oncology drugs Jakavi (ruxolitinib), Tasigna (nilotinib) and Farydak (panobinostat). In addition, Sandoz, the arm of Novartis that produces generics and biosimilars, will present data from PROTECT 2, one of its pivotal Phase III trials investigating their proposed pegfilgrastim biosimilar in patients with chemotherapy-induced neutropenia.

Bruno Strigini, who is president of Novartis Oncology, says: "We pride ourselves in our drive for new science and innovation, and look forward to bringing this promise to life at ASH through the results of our latest haematology research. We will be presenting encouraging overall survival data for both investigational and approved products, underscoring our commitment to improve and extend people's lives."

Lilian Anekwe

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches